Jeil Pharmaceutical Co.,Ltd (KRX:271980)
South Korea · Delayed Price · Currency is KRW 14,030
-40 (-0.28%)
At close: Nov 4, 2025
KRX:271980 Revenue
Jeil Pharmaceutical Co.,Ltd had revenue of 137.63B KRW in the quarter ending June 30, 2025, a decrease of -20.53%. This brings the company's revenue in the last twelve months to 661.60B, down -5.55% year-over-year. In the year 2024, Jeil Pharmaceutical Co.,Ltd had annual revenue of 704.54B, down -3.01%.
Revenue (ttm)
661.60B
Revenue Growth
-5.55%
P/S Ratio
0.31
Revenue / Employee
698.63M
Employees
947
Market Cap
201.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 704.54B | -21.85B | -3.01% |
| Dec 31, 2023 | 726.39B | 4.16B | 0.58% |
| Dec 31, 2022 | 722.23B | 21.54B | 3.07% |
| Dec 31, 2021 | 700.69B | 9.37B | 1.36% |
| Dec 31, 2020 | 691.32B | 19.92B | 2.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |